CN109321600A - A kind of method and its application of ox that cultivating production low irritability milk - Google Patents
A kind of method and its application of ox that cultivating production low irritability milk Download PDFInfo
- Publication number
- CN109321600A CN109321600A CN201811219908.6A CN201811219908A CN109321600A CN 109321600 A CN109321600 A CN 109321600A CN 201811219908 A CN201811219908 A CN 201811219908A CN 109321600 A CN109321600 A CN 109321600A
- Authority
- CN
- China
- Prior art keywords
- milk
- gene
- diallele
- cow
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 111
- 210000004080 milk Anatomy 0.000 title claims abstract description 111
- 239000008267 milk Substances 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 206010022998 Irritability Diseases 0.000 title claims abstract description 22
- 108050008461 Beta-lactoglobulin Proteins 0.000 claims abstract description 147
- 241000283690 Bos taurus Species 0.000 claims abstract description 60
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims abstract description 33
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 19
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 19
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 19
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 18
- 231100000221 frame shift mutation induction Toxicity 0.000 claims abstract description 9
- 230000037433 frameshift Effects 0.000 claims abstract description 9
- 230000035772 mutation Effects 0.000 claims abstract description 7
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 6
- 238000011161 development Methods 0.000 claims abstract description 5
- 210000000287 oocyte Anatomy 0.000 claims abstract description 4
- 210000004291 uterus Anatomy 0.000 claims abstract description 4
- 230000035606 childbirth Effects 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 230000009261 transgenic effect Effects 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 22
- 206010070834 Sensitisation Diseases 0.000 claims description 21
- 230000008313 sensitization Effects 0.000 claims description 21
- 238000003209 gene knockout Methods 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 238000013467 fragmentation Methods 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 abstract description 10
- 201000010859 Milk allergy Diseases 0.000 abstract description 9
- 108010060630 Lactoglobulins Proteins 0.000 abstract description 8
- 102000008192 Lactoglobulins Human genes 0.000 abstract description 8
- 238000011534 incubation Methods 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 108091029865 Exogenous DNA Proteins 0.000 abstract description 4
- 238000009395 breeding Methods 0.000 abstract description 4
- 230000001488 breeding effect Effects 0.000 abstract description 4
- 230000010354 integration Effects 0.000 abstract description 4
- 239000000843 powder Substances 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 235000020247 cow milk Nutrition 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 238000011049 filling Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 230000029087 digestion Effects 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 229940111202 pepsin Drugs 0.000 description 10
- 102000057297 Pepsin A Human genes 0.000 description 9
- 108090000284 Pepsin A Proteins 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000013566 allergen Substances 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000283725 Bos Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101150017501 CCR5 gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 101150034785 gamma gene Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000001175 peptic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 1
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 1
- XUCHENWTTBFODJ-FXQIFTODSA-N Ala-Met-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O XUCHENWTTBFODJ-FXQIFTODSA-N 0.000 description 1
- RMAWDDRDTRSZIR-ZLUOBGJFSA-N Ala-Ser-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RMAWDDRDTRSZIR-ZLUOBGJFSA-N 0.000 description 1
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 1
- WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 description 1
- WHLDJYNHXOMGMU-JYJNAYRXSA-N Arg-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WHLDJYNHXOMGMU-JYJNAYRXSA-N 0.000 description 1
- ANAHQDPQQBDOBM-UHFFFAOYSA-N Arg-Val-Tyr Natural products CC(C)C(NC(=O)C(N)CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O ANAHQDPQQBDOBM-UHFFFAOYSA-N 0.000 description 1
- VTYQAQFKMQTKQD-ACZMJKKPSA-N Asp-Ala-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O VTYQAQFKMQTKQD-ACZMJKKPSA-N 0.000 description 1
- WCFCYFDBMNFSPA-ACZMJKKPSA-N Asp-Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O WCFCYFDBMNFSPA-ACZMJKKPSA-N 0.000 description 1
- 101001008231 Bos taurus Beta-lactoglobulin Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- YRKJQKATZOTUEN-ACZMJKKPSA-N Cys-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N YRKJQKATZOTUEN-ACZMJKKPSA-N 0.000 description 1
- WZZGXXNRSZIQFC-VGDYDELISA-N Cys-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CS)N WZZGXXNRSZIQFC-VGDYDELISA-N 0.000 description 1
- NITLUESFANGEIW-BQBZGAKWSA-N Cys-Pro-Gly Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O NITLUESFANGEIW-BQBZGAKWSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- JRHPEMVLTRADLJ-AVGNSLFASA-N Gln-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JRHPEMVLTRADLJ-AVGNSLFASA-N 0.000 description 1
- QKWBEMCLYTYBNI-GVXVVHGQSA-N Gln-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O QKWBEMCLYTYBNI-GVXVVHGQSA-N 0.000 description 1
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 1
- SAEBUDRWKUXLOM-ACZMJKKPSA-N Glu-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O SAEBUDRWKUXLOM-ACZMJKKPSA-N 0.000 description 1
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 1
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 1
- WSWWTQYHFCBKBT-DVJZZOLTSA-N Gly-Thr-Trp Chemical compound C[C@@H](O)[C@H](NC(=O)CN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O WSWWTQYHFCBKBT-DVJZZOLTSA-N 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- OEROYDLRVAYIMQ-YUMQZZPRSA-N His-Gly-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O OEROYDLRVAYIMQ-YUMQZZPRSA-N 0.000 description 1
- FYTCLUIYTYFGPT-YUMQZZPRSA-N His-Gly-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FYTCLUIYTYFGPT-YUMQZZPRSA-N 0.000 description 1
- VCBWXASUBZIFLQ-IHRRRGAJSA-N His-Pro-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O VCBWXASUBZIFLQ-IHRRRGAJSA-N 0.000 description 1
- 101000595674 Homo sapiens Pituitary homeobox 3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- KTFHTMHHKXUYPW-ZPFDUUQYSA-N Leu-Asp-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KTFHTMHHKXUYPW-ZPFDUUQYSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- FIYMBBHGYNQFOP-IUCAKERBSA-N Leu-Gly-Gln Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N FIYMBBHGYNQFOP-IUCAKERBSA-N 0.000 description 1
- JKSIBWITFMQTOA-XUXIUFHCSA-N Leu-Ile-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O JKSIBWITFMQTOA-XUXIUFHCSA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- YESNGRDJQWDYLH-KKUMJFAQSA-N Leu-Phe-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N YESNGRDJQWDYLH-KKUMJFAQSA-N 0.000 description 1
- FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 description 1
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 1
- IZJGPPIGYTVXLB-FQUUOJAGSA-N Lys-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IZJGPPIGYTVXLB-FQUUOJAGSA-N 0.000 description 1
- BXPHMHQHYHILBB-BZSNNMDCSA-N Lys-Lys-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BXPHMHQHYHILBB-BZSNNMDCSA-N 0.000 description 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 description 1
- AETNZPKUUYYYEK-CIUDSAMLSA-N Met-Glu-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O AETNZPKUUYYYEK-CIUDSAMLSA-N 0.000 description 1
- NHDMNXBBSGVYGP-PYJNHQTQSA-N Met-His-Ile Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)CC1=CN=CN1 NHDMNXBBSGVYGP-PYJNHQTQSA-N 0.000 description 1
- AXHNAGAYRGCDLG-UWVGGRQHSA-N Met-Lys-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AXHNAGAYRGCDLG-UWVGGRQHSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- WGXOKDLDIWSOCV-MELADBBJSA-N Phe-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O WGXOKDLDIWSOCV-MELADBBJSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 1
- NUZHSNLQJDYSRW-BZSNNMDCSA-N Pro-Arg-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O NUZHSNLQJDYSRW-BZSNNMDCSA-N 0.000 description 1
- HJSCRFZVGXAGNG-SRVKXCTJSA-N Pro-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1 HJSCRFZVGXAGNG-SRVKXCTJSA-N 0.000 description 1
- VDGTVWFMRXVQCT-GUBZILKMSA-N Pro-Glu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 VDGTVWFMRXVQCT-GUBZILKMSA-N 0.000 description 1
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 1
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- RKDFEMGVMMYYNG-WDCWCFNPSA-N Thr-Gln-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O RKDFEMGVMMYYNG-WDCWCFNPSA-N 0.000 description 1
- KGKWKSSSQGGYAU-SUSMZKCASA-N Thr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KGKWKSSSQGGYAU-SUSMZKCASA-N 0.000 description 1
- GKWNLDNXMMLRMC-GLLZPBPUSA-N Thr-Glu-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O GKWNLDNXMMLRMC-GLLZPBPUSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- OENGVSDBQHHGBU-QEJZJMRPSA-N Trp-Glu-Asn Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OENGVSDBQHHGBU-QEJZJMRPSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- SZTTYWIUCGSURQ-AUTRQRHGSA-N Val-Glu-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SZTTYWIUCGSURQ-AUTRQRHGSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 108010066270 beta-lactorphin Proteins 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 108010040856 glutamyl-cysteinyl-alanine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 108010044538 lactostatin Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- XKPKPGCRSHFTKM-UHFFFAOYSA-L magnesium;diacetate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].CC([O-])=O.CC([O-])=O XKPKPGCRSHFTKM-UHFFFAOYSA-L 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 108010000998 wheylin-2 peptide Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0273—Cloned vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/101—Bovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of method and its application of ox for cultivating production low irritability milk.This method comprises the following steps: importing Zinc finger nuclease carrier pZFN to bovine fibroblasts, obtains the donorcells that genotype is diallele saltant type;Diallele saltant type is that frameshift mutation occurs for the nucleic acid molecule of the β-LG gene on two homologues of ox;The nucleus of donorcells is moved into the bovine oocyte for removing nucleus, development forms reconstruct embryo, then moves into cow uteri, and childbirth obtains the ox of production low irritability milk.Successful incubation of the present invention without exogenous DNA integration, can produce no beta lactoglobulin milk and mutation passed to by follow-on β-LG diallele by normal breeding and knock out ox.The present invention is to solve the problems, such as that milk allergy lays important foundation, while also will provide unlimited possibility for the preparation of humanization milk.The present invention has important application value.
Description
Technical field
The invention belongs to field of biotechnology, and in particular to it is a kind of cultivate production low irritability milk ox method and its
Using.
Background technique
Milk is the healthy food that the important nutrition of worldwide edible one kind is in admirable proportion, including protein abundant,
Carbohydrate, fat element and minerals.Although Nutrition Management and Quantitative Genetics improve ox by the Breeding Strategies of many years
The yield of milk, still, the ingredient of milk there is no significant changes.It is especially right with the development of biotechnology and genetic engineering
Animal husbandry breed improvement provides bigger chance to prepare " the design mode milk " of the suitable mankind.Up to now, various Gao Pin
Matter transgenic cow, which is reported that, for example expresses restructuring lactoferrin ox, increases milk casein content ox, anti-mammitis
Ox, anti-rabid ox disease ox, improve animal welfare polled cattle.But the allergic reaction problem of milk at present still cannot be fine
Ground solves.
Beta lactoglobulin (β-lactoglobulin, β-LG) is the main allergen in milk, and Milk allergy is in baby children
It is most commonly seen in youngster's food hypersenstivity.Foreign Epidemic disease investigation result shows that the disease incidence of infant's cow milk protein allergy is
0.3%-3.5%, and have the tendency that constantly rising, it seriously affects infant and nutriment in dairy products is absorbed and utilized.So far
Until the present, researcher has attempted to multiple technologies to reduce the sensitization of β-LG in cow's milk, mainly includes heat treating process, high pressure
Method, enzymatic isolation method and glycosylation modification method etc..Although these methods reduce the sensitization of β-LG, milk to a certain extent
In the structure and functions of other albumen destroyed, the trophism of milk substantially reduces, and the sensitization of β-LG can not yet
It completely eliminates.β-LG sensitization how is effectively reduced, while keeping the original structure and function of albumen as far as possible again, at present state
Inside and outside all not effective and feasible technical method.
2001, Bibikova et al. was successfully mediated in Xenopus Oocytes using Zinc finger nuclease homologous for the first time
Recombination, Zinc finger nuclease technology causes the extensive attention of biological field, be widely used in animal and plant gene deletion,
Reparation, large fragment DNA are deleted and the fixed point of gene is inserted into etc..Zinc finger nuclease-mediated High-efficiency gene Knockout technology is
It is combined with human disease treatment, phase clinical trial is successfully completed by the Zinc finger nuclease that Sigma Co., USA designs,
As a result exciting.They formulate Zinc finger nuclease (the HIV disease of specific bond mankind's CCR5 gene by way of genetic engineering
Poison utilizes CCR5 gene coded protein, infects the CD4+ cell of people) so that the gene inactivates, to resist invading for inhibition of HIV
Dye.The CD4+ cell (CCR5 gene knockout) that Zinc finger nuclease modified is injected by patient HIV receives 6 HIV diseases for the treatment of
In people, there is 5 immunocyte quantity to significantly rise.Urnov et al. utilizes the reparation of Zinc finger nuclease-mediated IL2R γ gene
(immune deficiency disorder), can with the mutation IL2R γ gene (efficiency is up to 18%) of repair cell, to restore the gene expression,
The T cell of immune performance is shown as, provides a good therapy approach for immunodefiiciency patient.Hockemeyer etc.
People modifies OCT4 and PITX3 gene using Zinc finger nuclease in human stem cells, it was demonstrated that Zinc finger nuclease can be dry thin
The gene of different expressions is efficiently acted in born of the same parents, has established certain basis for stem-cell therapy.Zinc finger nuclease-mediated
High-efficiency gene Knockout technology is combined with somatic cell clone technique, and Whyte et al., which has been obtained, utilizes Zinc finger nuclease
The clone pig of GFP gene knockout is mediated, gene knockout efficiency is up to 5%.In addition, the scientific research of Chinese scholar professor Lai Liangxue leader
Team also successfully utilizes the PPAR- γ gene knockout of Zinc finger nuclease-mediated pig, obtains corresponding gene knockout clone pig.
Summary of the invention
The purpose of the present invention is the oxen of production low irritability milk or cultivation production low irritability milk.
The present invention protects the method for cultivating the ox of production low irritability milk first.
The present invention is to be protected to cultivate the method for producing the ox of low irritability milk, concretely method one, it may include such as
Lower step: inhibit to set out the synthesis of β-LG albumen and/or expression quantity and/or activity in cow genome group, obtains transgenic cow;With go out
Hair ox is compared, and the milk sensitization of transgenic cow production reduces.
In the above method one, described " inhibition is set out the synthesis of β-LG albumen and/or expression quantity and/or work in cow genome group
Property " can be carried out by way of gene site-directed editor, RNA interference, homologous recombination or gene knockout;The gene site-directed editor can
It is carried out using cow genome group editor's carrier.
In the above method one, described " inhibition is set out the synthesis of β-LG albumen and/or expression quantity and/or work in cow genome group
Property " it can be that frameshift mutation is occurred into for the nucleic acid molecule of the β-LG gene on two homologues for the ox that sets out.
The present invention is to be protected to cultivate the method for producing the ox of low irritability milk, concretely method two, it may include step
Suddenly (1): importing cow genome group editor's carrier to bovine fibroblasts, it is thin to obtain the donor that genotype is diallele saltant type
Born of the same parents;
The diallele saltant type is that the nucleic acid molecule of the β-LG gene on two homologues of ox occurs
Change, it is this to change the synthesis for inhibiting β-LG albumen and/or expression quantity and/or activity.
It is described " nucleic acid molecule of the β-LG gene on two homologues of ox changes " in the above method two
Frameshift mutation can occur for the nucleic acid molecule of the β-LG gene on two homologues of ox.
Any of the above-described the method two may also include step (2): after completing step (1), by the cell of the donorcells
Core moves into the bovine oocyte for removing nucleus, and development forms reconstruct embryo, then moves into cow uteri, it is low that childbirth obtains production
The ox of sensitization milk.
In the above method two, the bovine fibroblasts can specifically be digested by bovine fetal fibroblast system to be obtained.
In the above method two, described " importing cow genome group editor carrier to bovine fibroblasts " is concretely to ox at fibre
Tie up the mRNA that cell imports cow genome group editor's carrier.
Any of the above-described cow genome group editor carrier can be Zinc finger nuclease carrier pZFN;The Zinc finger nuclease carrier
The target DNA that pZFN is identified in cow genome group is the DNA fragmentation for encoding β-LG albumen.
The recognition site of any of the above-described Zinc finger nuclease carrier pZFN is concretely in sequence table shown in sequence 4
DNA molecular.
The method of the present invention ox to be protected for cultivating production low irritability milk, concretely method three, can be selection
The Niu Jinhang breeding for the production low irritability milk that any of the above-described method is cultivated.
The present invention also protect it is a kind of detection or auxiliary detection milk sensitization method, it may include following steps: detection to
β-LG the gene surveyed on two homologues of ox is wild type or diallele saltant type, and genotype is double equipotential bases
The sensitization of the milk produced by the ox to be measured of saltant type be lower than or it is candidate lower than genotype be wild type ox to be measured;It is described double
Allelic variants are that frameshift mutation occurs for the nucleic acid molecule of the β-LG gene on two homologues of ox;It is described
Wild type is that frameshift mutation does not occur for the nucleic acid molecule of the β-LG gene on two homologues of ox.
In the above method, the anaphylactogen of the sensitization can be β-LG albumen.
The present invention also protects the Zinc finger nuclease carrier pZFN of cow genome group editor a kind of;The Zinc finger nuclease carrier
The target DNA that pZFN is identified in cow genome group can be the DNA fragmentation of coding β-LG albumen.
The recognition site of the Zinc finger nuclease carrier pZFN can be DNA molecular shown in sequence 4 in sequence table.
The present invention also protects the nucleic acid molecule of the β-LG gene on two homologues by ox that frameshit occurs and dashes forward
The method or product of change or will inhibit in cow genome group the synthesis of β-LG albumen and/or expression quantity and/or active method or
Product in the ox and/or reduction milk sensitization of cultivating production low irritability milk and/or produces answering in low irritability milk
With.
In above-mentioned application, frameshit occurs for the nucleic acid molecule of the β-LG gene on two homologues by ox
The product of mutation concretely any of the above-described Zinc finger nuclease carrier pZFN.
In above-mentioned application, frameshit occurs for the nucleic acid molecule of the β-LG gene on two homologues by ox
The method of mutation concretely any of the above-described the method two.
" it is prominent that frameshit occurs for the nucleic acid molecule of the β-LG gene on two homologues of ox described in any of the above-described
Become " concretely 265-281 nucleotide deletion (nucleosides of β-LG gene at this time of β-LG gene on one article of homologue
Acid sequence is as shown in sequence 2 in sequence table) while β-LG 265-282 nucleotide of gene on another article of homologue
It lacks (nucleotide sequence of β-LG gene is as shown in sequence 3 in sequence table at this time).
The nucleotide sequence of any of the above-described β-LG gene can be as shown in sequence 1 in sequence table.
The amino acid sequence of any of the above-described β-LG albumen is as shown in sequence 5 in sequence table.
The β-of the present inventor's first passage Zinc finger nuclease (ZFNs) technology successful incubation without exogenous DNA integration
LG diallele knocks out ox, and generates the milk without beta lactoglobulin.Balb/c is carried out to the milk of no beta lactoglobulin
The Allergenicity assessment of mouse model is tested, it is found that it can trigger more compared with ordinary milk (milk that non-transgenic cow produces)
Low allergic reaction, the generation including allergen specificity Immunoglobulin IgE;The milk without beta lactoglobulin is in 2min simultaneously
When be easy to by pepsin digestion, and the beta lactoglobulin in ordinary milk (non-transgenic cow produce milk) is after 60min
Digestion completely not yet, the combination of the IgE and the milk without beta lactoglobulin of milk allergy (CMA) patient are significant to be lower than ordinary milk
(milk that non-transgenic cow produces).Importantly, exogenous DNA will not be introduced receptor by the technology, base can be mitigated in this way
The bio-safety problem being related to by editor animal.Finally, β-LG diallele knocks out ox can will be mutated by normal breeding
Pass to the next generation.These researchs also will be " humanization milk " to solve the problems, such as that milk allergy lays important foundation
Preparation offer is infinitely possible, so that milk is more suitable for human health, and improve the functional characteristic of milk.The present invention has important answer
With value.
Detailed description of the invention
Fig. 1 is the flow chart cultivated β-LG diallele and knock out ox.
Fig. 2 is the recognition site position view of pZFN.
Fig. 3 is the photo that β-LG diallele knocks out ox.
Fig. 4 is the testing result of β-LG albumen in 2 milk of embodiment.
Fig. 5 is the testing result of simulate the gastric juice digestion experiment.
Fig. 6 is the testing result of people's serum test.
Fig. 7 is the testing result of animal model experiment.
Specific embodiment
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.
Experimental method in following embodiments is unless otherwise specified conventional method.
Test material as used in the following examples is unless otherwise specified to buy from routine biochemistry reagent shop
It arrives.
Quantitative test in following embodiment, is respectively provided with three repeated experiments, and results are averaged.
Wild holstein cow is non-transgenic cow.
The PBS buffer solution (hereinafter abbreviation PBS buffer solution) of pH7.2,0.01mM, FBS and DMEM culture medium are Gibco
The product of company.A23178 is the product of Sigma company.Shock by electricity the product that liquid is Lonza company.
Embodiment 1 cultivates β-LG diallele knockout ox using Zinc finger nuclease
Ox is diploid animal, when Zinc finger nuclease plays a role, on same two intracellular homologues
Two allele be likely to be edited, generate same-type or different types of mutation.β-the LG that the present embodiment obtains
Diallele knocks out ox (β-LG-/Ox) be two homologues β-LG gene be mutated and mutant form not
Together.The present inventor cultivates β-LG diallele using Zinc finger nuclease and knocks out ox, considers the industrialization in later period, avoids
Biosafety issues do not use riddled basins, while using ZFNs mRNA, can cultivate no exogenous DNA integration in this way
β-LG diallele knock out ox, technology path is detailed in Fig. 1.
One, ZFN plasmid is synthesized
According to the sequence information of ox β-LG gene (shown in sequence 1 in sequence table), zinc finger core is synthesized by the design of sigma company
Sour zymophore pZFN.PZFN is made of two plasmids, and targeting sequence is located at the First Exon of β-LG gene.Specific such as Fig. 2
Shown in (BLG, that is, β-LG gene).
The recognition site of pZFN are as follows: CCCAGGCCCTCATTGTCacccagACCATGAAGGGCCTGGA (sequence in sequence table
Column 4), β-LG 257-296 nucleotide of gene shown in sequence 1 in corresponding sequence table.Wherein, two terminal sequence
(CCCAGGCCCTCATTGTC and ACCATGAAGGGCCTGGA) is zinc finger binding site, and middle section sequence (acccag) is to cut
Cut site.
Two, the fibroblastic acquisition of saltant type
1, the acquisition of bovine fetal fibroblast system
Take the ear skin tissue of holstein cow, it is clear with 70% (v/v) alcohol water blend after ear's lower edge back side unhairing
Wash clean, then pick from ear's lower edge back side with blade that take area be 1cm2The skin of left and right, is placed in 0 DEG C of DMEM/F12 culture medium
In transport laboratory back as early as possible, with PBS buffer solution and 70% (v/v) alcohol water blend cleaning shred into 1mm afterwards several times3What is controlled is small
Block, DMEM culture medium plants block in batches after cleaning 2 times in the DMEM culture medium culture bottle containing 1mL containing 10% (v/v) FBS, (specification is
25cm2) in, the DMEM culture medium containing 10% (v/v) FBS is added again after tissue block adherent is secured to 6mL, 37 DEG C, 5%CO2Training
Case culture 6-7d is supported, during which every 2d is changed liquid 1 time, after cell growth converges, passed on 2-3 times with 0.25% trypsin digestion,
It is frozen in batches with the DMEM culture medium containing 20% (v/v) FBS, 10% (v/v) DMSO.In this way, through originally culture, secondary culture,
The operation of the in vitro cultures such as freezing, establishes holstein cow fibroblast.
2, the mRNA transfection of ZFNs
(1) 2d before transfecting obtains bovine fibroblasts with trypsin digestion bovine fetal fibroblast system to unicellular
(also referred to as wild type fibroblast);By 1 × 106A bovine fibroblasts are forwarded to culture bottle (specification 100mL), are added
4mL contains the DMEM culture solution of 10% (v/v) fetal calf serum, 37 DEG C, 5%CO2It cultivates to logarithmic growth phase.
(2) after completing step (1), the bovine fibroblasts in logarithmic growth phase are taken, with trypsin digestion, then
1000g is centrifuged 5min, collects precipitating.
(3) after completing step (2), the precipitating is taken, is washed 1 time with PBS buffer solution, is then resuspended with 100 μ L electric shock liquid,
Obtain cell suspension.
(4) take cell suspension (containing 1 × 106A cell), it (will be in step 1 by the 4 μ g ZFNs mRNA being transcribed in vitro
The Zinc finger nuclease carrier pZFN of sigma company design synthesis is linearized and using it as template, according to the mRNA of Ambion company
The operating procedure of in-vitro transcription kit obtains) it mixes well rear corotation and enters the cup that shocks by electricity, shocked by electricity (electric field strength 1.2KV/
Cm, burst length 1ms).
(5) after completing step (4), the cell after electric shock is transferred to culture bottle (specification 100mL), 4mL is added and contains 10%
(v/v) the DMEM culture solution of fetal calf serum, 37 DEG C, 5%CO21-2d is cultivated, Transfected cells are obtained.
3, infinite dilution method prepares single cell clone and genotype identification
(1) when the Transfected cells culture for obtaining above-mentioned steps 2 to fusion rate reaches 80%-90%, with the 0.1% of 37 DEG C
Cell is collected by centrifugation after the DMEM culture medium containing 10% (v/v) FBS terminates digestion in pancreatin digestion.
(2) cell is resuspended with the DMEM culture medium containing 20% (v/v) FBS, takes part cell to be counted, cell is diluted
To 100/mL, cell suspending liquid is obtained.In the culture dish for having added DMEM culture medium of the 9mL containing 20% (v/v) FBS to 20
It is each that 1mL cell suspending liquid, 37 DEG C, 5%CO are added2, cultivate under the conditions of saturated humidity.
(3) when the cell clone in culture dish grows to diameter and reaches 2mm or more, culture medium is removed, after DPBS is rinsed, is used
Clone's ring covers in cloning cluster, and 0.1% pancreatin of 37 DEG C of about 100 μ L is added dropwise thereto, after digesting about 3min, is added dropwise and contains 20%
(v/v) the DMEM culture medium of FBS terminates digestion, transfers them to after gently blowing and beating and expands culture in 48 orifice plates.
When cell confluency is up to 90% in (4) 48 orifice plates, take a semicell for cell clone genotype identification after digestion,
Remaining half continuation is cultivated in the orifice plate.
(5) cell for identifying genotype abandons supernatant after 1000g is centrifuged 5min, is added according to cell precipitation amount
10-20 μ L cell pyrolysis liquid.
(6) drawing 3 μ L cell pyrolysis liquids is that template carries out PCR identification, (is set according to ox β-LG gene with the primer in table 1
Count and synthesize) carry out PCR amplification.
Table 1
Reaction system is 20 μ L, (dense by 1.0 μ L DNA profilings, 0.4 μ L primer P1 (concentration is 10 μM), 0.4 μ L primer P2
Degree is 10 μM), 0.4 μ L dNTP, 0.3 μ L LA archaeal dna polymerase, 2.0 μ 10 × PCR of L Buffer and 15.5 μ L ddH2O groups
At.
Response procedures: 94 DEG C of 5min;94 DEG C of 30s, 52 DEG C of 30s, 72 DEG C of 1min, 35 circulations;72 DEG C of 5min, 4 DEG C of preservations.
Pcr amplification product is purified, is sequenced.If producing mutation in ZFNs action site, sequencing result will appear
Double-peak Phenomenon determines that the cell line is mutant.And then the PCR product of mutant is connected to pMD-19t plasmid vector, it converts
After E. coli competent, the multiple single colonies of picking are sequenced, and sequencing result is compared with wild-type beta-LG gene, is obtained
Obtain detailed abrupt information.
The result shows that in 128 single cell clones, obtain one be diallele be mutated and cause frameshift mutation (-
Single cell clone 16bp/-17bp).Specifically, β-LG gene is the β-LG base of a homologue in the single cell clone
265-281 nucleotide deletions of cause, and the missing of the β-LG 265-282 nucleotide of gene of another article of homologue.
The single cell clone is named as saltant type fibroblast.
β-LG gene in wild type fibroblast genome is wild-type beta-LG gene (1 institute of sequence in sequence table
Show).β-LG gene in saltant type fibroblast genome is by β-LG gene 265-281 of one article of homologue
The β-of nucleotide deletion (nucleotide sequence of β-LG gene is as shown in sequence 2 in sequence table at this time) and another homologue
The missing (nucleotide sequence of β-LG gene is as shown in sequence 3 in sequence table at this time) of LG 265-282 nucleotide of gene, obtains
The DNA molecular arrived.
It follows that saltant type fibroblast and wild type is fibroblastic is different only in that: being on β-LG gene
It is no that there are the missings of 265-281 nucleotide and 265-282 nucleotide in sequence 1.
Three, β-LG diallele knocks out the cultivation of ox
1, the saltant type fibroblast in logarithmic growth phase is taken, with 0.25% trypsin digestion 5min, obtains list
Cell.
2, in the unicellular immigration non-nucleus egg mother cell oolemma for obtaining step 1, first it is placed in Zimmerman liquid
(100mL Zimmerman liquid is by sucrose 0.9854g, Magnesium acetate (Mg(OAc)2) tetrahydrate 10.7mg, Calcium diacetate monohydrate 1.8mg, phosphoric acid hydrogen two
Potassium 7.4mg, reduced glutathione 3.1mg, bovine serum albumin 1.0mg and water composition) in balance 3-5min, then be placed in integration slot
Interior rotation egg cell contacts donorcells with egg mother cell and vertical with electric field, while in the direct current arteries and veins that field strength is 2.5kV/cm
It rushes in field, (fusion instrument is BTX public for fusion under conditions of the burst length is 10 μ s, pulse number is 2 times, the pulse spacing is 1s
The product of department, model ECM-2001), rapid M199 liquid (product of Gibco company) of the immigration containing 10% (v/v) FBS, 37
DEG C, 5%CO2 cultivate 30min, obtain reconstructed embryo.
3, the CR1aa culture solution for the Calcium ionophore A23178 that concentration is 5 μM is added in the reconstructed embryo for taking step 2 to obtain
(100mL CR1aa culture solution is by 0.67g sodium chloride, 0.023g potassium chloride, 0.22g sodium bicarbonate, 2mg Sodium Pyruvate, 100 μ l
Phenol red and water composition) processing 5min;Liquid phase is abandoned, is added containing 5 μ g/mL cytochalasin Bs and 10 μ g/mL cycloheximides
CR1aa culture solution handles 5h (purpose is activation reconstituted embryo);Abandoning liquid phase, CR1aa culture solution of the addition containing 5% (v/v) FBS, 37
DEG C, 5%CO2 cultivate 48h, observe cleavage rates, 7-8d observe blastocyst rate.
4, the excellent transgene clone blastaea of the form that 7d is cultivated in step 3 is moved into the cornua uteri of the receptor cow of the same period
Interior (co-transplantation receptor cow 3) obtains β-LG diallele and knocks out ox (i.e. No. 111027 oxen).
Using blood and tissue gene group reagent box (QIAGEN company) extract ox to be measured (No. 111027 oxen or wild lotus this
Smooth milk cow) ear tissue genomic DNA, and using it as template, using the primer pair of primer P1 and primer P2 (shown in table 1) composition
PCR amplification is carried out, pcr amplification product is obtained.Pcr amplification product is purified, is sequenced.
Sequencing result shows that genotype of the wild holstein cow based on β-LG gene is wild type (β-LG+/+),
Genotype of No. 111027 oxen based on β-LG gene is diallele saltant type (β-LG-/-).Diallele saltant type is
β-LG 265-281 nucleotide deletions of gene of one article of homologue, and the β-LG gene of another article of homologue
The missing of 265-282 nucleotide.Due to lacking 16bp and 17bp respectively, β-LG gene frameshift mutation, and then β-LG egg are caused
White afunction.
No. 111027 oxen survive normally at present, see Fig. 3.
Embodiment 2, detection β-LG diallele knock out and whether there is β-LG albumen in the milk of ox
One, SDS-PAGE, which detects β-LG diallele and knocks out, whether there is β-LG albumen in the milk of ox
1, with ox to be measured (β-LG diallele knock out ox or wild holstein cow) the 1st day, the 3rd day lactation period or the
The milk of production in 5 days extracts total protein.
2, the total protein and β-LG protein standard substance (product of Sigma company) for the ox to be measured for taking step 1 to obtain respectively, into
Row SDS-PAGE.
Experimental result is shown in A in Fig. 4 (M is albumen Marker, and β-LG is β-LG protein standard substance).The result shows that β-LG is double
The total protein that allele knocks out ox does not detect the expression of β-LG albumen, it is seen that β-LG diallele knocks out the ox that ox produces
There is no β-LG albumen in milk.
Two, Western blot, which detects β-LG diallele and knocks out, whether there is β-LG albumen in the milk of ox
1, with ox to be measured (β-LG diallele knock out ox or wild holstein cow) the 1st day, the 3rd day lactation period or the
The milk of production in 5 days extracts total protein.
2, the total protein and β-LG protein standard substance for the ox to be measured for taking step 1 to obtain respectively carry out Western blot.It adopts
Use Bovine beta-lactoglobulin Antibody (product of BETHYL company) as primary antibody, goat antibody (middle China fir
The product of company of Golden Bridge) as secondary antibody detection β-LG albumen.
Experimental result is shown in B in Fig. 4 (β-LG is β-LG protein standard substance).The result shows that β-LG diallele knocks out ox
Total protein do not detect the expression of β-LG albumen, it is seen that β-LG diallele, which knocks out in the milk that ox produces, does not have β-LG egg
It is white.
After the above results show that the β-LG gene of β-LG diallele knockout ox is destroyed, do not contained in the milk of production
β-LG albumen.
Embodiment 3, β-LG diallele knock out the sensitization detection of the milk of ox
Dry powder is made in the milk that ox to be measured (β-LG diallele knocks out ox or wild holstein cow) produces, is named as
Milk powder to be measured.
One, simulate the gastric juice digestion experiment
A kind of native protein will keep the sensitization of itself, and the amino acid fragment at the IgE binding site of the albumen is general
It can be resistant to the digestion of internal gastrointestinal tract, be possible to be absorbed and be immunoreacted after arrival mucous membrane of small intestine in this way.Therefore, in body
Still remaining protein fragments after outer simulation digestion 60min, are considered extremely difficult digestion, and have the possibility of sensitization.
Simulation peptic digest liquid is pH value, salt ionic concentration and the digestion of pepsin concn setting simulated in human gastric juice
Liquid detects simulation gastro-intestinal Fluid exogenous proteins with reference to Ministry of Agriculture's genetically modified organism and products thereof edible safety and digests stability test
Method carries out, and pepsin (pepsin) (product of the Sigma company) vigor used in this standard cannot be below 2000U/mg,
Additive amount A=5 × 10 of pepsin in 100mL simulate the gastric juice6(A-pepsin additive amount, unit are milligram to/19B
(mg);B-peptic activity of stomach, unit are every milligram of unit vigor (U/mg)).Preparation system: 0.2g sodium chloride is weighed
(NaCl) and Amg pepsin 70mL double distilled water, is added, is added 730 μ L hydrochloric acid, then with hydrochloric acid tune pH to 1.2, adds water constant volume
To 100mL.Matching while using.
Protein sample sample-loading buffer is the product of green skies company.
Specific step is as follows:
1, centrifuge tube is taken, 1.9mL is added and simulates peptic digest liquid, 37 DEG C of water bath with thermostatic control 5min.
2, after completing step 1,100 μ L milk amidin (concentration 5g/L) to be measured or double distilled water is added (as right
According to), vortex oscillation, then 37 DEG C of water-baths 0s, 15s, 2min, 15min, 30min or 60min sample 200 μ L.
3, a new centrifuge tube is separately taken, the sodium bicarbonate that the sampling and 70 μ L concentration that step 2 is added are 0.2mol/L is water-soluble
Liquid, ice bath 1min.
4, after completing step 3, the centrifuge tube is taken, 70 μ L protein sample sample-loading buffers are added, boiling water bath 5min takes out
It is cooled to room temperature after centrifuge tube.
5, by the liquid and pepsin (as control) progress SDS-PAGE in the centrifuge tube for completing step 4.
Experimental result is shown in Fig. 5, (left figure is wild holstein cow, and right figure is that β-LG diallele knocks out ox, and M is albumen
Marker, Pepsin are pepsin).The result shows that after simulate the gastric juice digests 60min, in non-transgenic cow milk powder
β-LG albumen does not digest yet, and the β-LG albumen that β-LG diallele knocks out in milk powder is easy to digest, has low irritability.
Two, human serum is tested
The test serum that this experiment is chosen is that (anaphylactogen of patient may be more in milk for the serum of milk allergy patient
Kind of allergic protein) and non-milk allergy healthy volunteer serum.
Allergen specificity antibody IgE expression in detection test serum is tested using Elisa.Suffer from if it is milk allergy
Person, serum and milk powder interaction, allergen specificity antibody IgE expression can be high, and the milk that β-LG gene knockout ox generates,
If the anaphylactogen of autopath is β-LG albumen, the expression that sensitization reduces IgE in then serum can be reduced.
But for healthy volunteer, allergen-specific antibody in serum IgE expression does not have king-sized influence.Specific steps are such as
Under: 1) non-transgenic cow milk powder with β-LG diallele is knocked out into milk powder bicarbonate buffer (pH9.6) and dissolved, and
It is separately added into 96 orifice plates in (2 hole μ g/), 4 DEG C of overnight incubations;2) by 96 orifice plates with PBST solution (0.05%Tween 20/PBS)
Washing is three times, each that 200 μ LBSA solution (1%BSA/PBS), 37 DEG C of incubation 1h are added;It 3), will be to be measured after PBST solution washs 3 times
Serum is added separately in 96 orifice plates in (100 hole μ L/) with 1:10 dilution, and 37 DEG C of incubation 1h are simultaneously washed 3 times with PBST solution;4) with
Biotin labeling is anti-human-and IgE antibody (product of Abcam company) is used as primary antibody, and rabbit source biotin antibody is as secondary antibody (Abcam
The product of company), after 37 DEG C of incubation 1h, microplate reader measures IgE expression.
Experimental result is shown in A in Fig. 6.The results show that β-LG gene knockout milk powder makes ox compared with non-transgenic cow milk powder
Milk autopath organizes IgE antibody expression in No. 9 and No. 10 patients serums and is remarkably decreased (P < 0.001), illustrates that β-LG very may be used
It can be the main allergen of No. 9 and No. 10 patients;IgE antibody expression in 7,8, No. 11 patients serums of milk allergy patient group
Decline (P < 0.01), IgE antibody expression does not have significant changes in No. 6 patients serums, thus it is speculated that β-LG be not its mainly or most
Main anaphylactogen.The above result shows that β-LG protein knockout, can reduce milk sensitization.,
The total protein for extracting milk powder to be measured carries out Western blot.Specific step is as follows: 1) milk powder total protein to be measured
Loading carries out SDS-PAGE respectively;2) in 350mA constant current transferring film to nitrocellulose filter;3) nitrocellulose filter is put into self-styled
In bag, 1h is closed with the diluted BSA closing room temperature of 5%TBST;4) using the serum of 9, No. 10 patient more sensitive to β-LG
Serum pond is blended together as primary antibody, and 4 DEG C are incubated overnight;5) with the anti-human-IgEdiluted 1:1000 (production of Abcam company of source of mouse
Product) it is secondary antibody, development.
Experimental result is shown in B in Fig. 6.The result shows that with non-transgenic cow milk powder (the i.e. milk of wild type milk cow milk preparation
Powder) it compares, β-LG diallele, which knocks out milk powder (i.e. the milk powder of β-LG gene knockout ox milk preparation), to be had significantly
Low irritability.
Three, animal model experiment
Cleaning grade female Balb/c mouse is the product of Beijing Vital River Experimental Animals Technology Co., Ltd., quality certification number
SCXK (capital) 2012-0001.
Cleaning grade normal diet is to assort the level of main nutrient composition, is processed into pellet;Then it passes through60Co spoke
Sterilizing is penetrated, feed is made to reach cleaning grade.The experiment that the level of cleaning grade normal diet reaches listed in GB14924-2010 is dynamic
Object trophic level.
Rearing conditions: this experiment carries out in SPF grades of animal houses of China Agricultural University's food and nutrition engineering college, qualified
Card number: SYXK (capital) 2010-0036.22~25 DEG C of environment temperature, relative humidity 40%~60%, 12h artificial light/dark is followed
Ring, 15 times/h of rate of ventilation.With every 4, the cage nursings of group animal, ad lib and drinking-water.
Take 96, the cleaning grade female Balb/c mouse that weight is 16-20g, cleaning grade normal diet adaptable fed 5 days
Afterwards, positive controls, negative control group, non-transgenic cow milk powder group 1, non-transgenic cow milk powder group 2, not are randomly divided by weight
Transgenic cow milk powder group 3, β-LG diallele knock out milk powder group 1, β-LG diallele knocks out milk powder group 2 and β-LG
Diallele knocks out totally 8 groups of milk powder group 3, and every group 12, being then handled as follows (needs to weigh mouse before each stomach-filling
Average weight, for adjusting the concentration of stomach-filling liquid):
Positive controls: respectively in experiment the 0th day, the 7th day, the 14th day, the 21st day and the 28th day, every mouse oral is filled
Stomach 0.2mL OVA solution;It tests the 42nd day, every mouse oral stomach-filling 2mL OVA solution;The concentration of OVA solution is 5mg/mL,
Solvent is PBS buffer solution;
Negative control group: respectively in experiment the 0th day, the 7th day, the 14th day, the 21st day and the 28th day, every mouse oral is filled
Stomach 0.2mL physiological saline;It tests the 42nd day, every mouse oral stomach-filling 2mL physiological saline;
Non- transgenic cow milk powder group 1: every small respectively in experiment the 0th day, the 7th day, the 14th day, the 21st day and the 28th day
The non-transgenic cow milk power solution of the oral stomach-filling 0.2mL of mouse (using the total protein content in non-transgenic cow milk powder as tested material, dosage
For 0.5mg total protein/gBW);It tests the 42nd day, every non-transgenic cow milk power solution of mouse oral stomach-filling 0.2mL is not (to turn
Total protein content in gene milk powder is tested material, and dosage is 5mg total protein/gBW);
Non- transgenic cow milk powder group 2: every small respectively in experiment the 0th day, the 7th day, the 14th day, the 21st day and the 28th day
The non-transgenic cow milk power solution of the oral stomach-filling 0.2mL of mouse (using the total protein content in non-transgenic cow milk powder as tested material, dosage
For 1mg total protein/gBW);It tests the 42nd day, every non-transgenic cow milk power solution of mouse oral stomach-filling 0.2mL is not (to turn base
Because the total protein content in milk powder is tested material, dosage is 10mg total protein/gBW);
Non- transgenic cow milk powder group 3: every small respectively in experiment the 0th day, the 7th day, the 14th day, the 21st day and the 28th day
The non-transgenic cow milk power solution of the oral stomach-filling 0.2mL of mouse (using the total protein content in non-transgenic cow milk powder as tested material, dosage
For 2mg total protein/gBW);It tests the 42nd day, every non-transgenic cow milk power solution of mouse oral stomach-filling 0.2mL is not (to turn base
Because the total protein content in milk powder is tested material, dosage is 20mg total protein/gBW);
β-LG diallele knocks out milk powder group 1: respectively in experiment the 0th day, the 7th day, the 14th day, the 21st day and the 28th
It, every mouse oral stomach-filling 0.2mL β-LG diallele knocks out milk powder solution and (knocks out milk with β-LG diallele
Total protein content in powder is tested material, and dosage is 0.5mg total protein/gBW);It tests the 42nd day, every mouse oral stomach-filling
0.2mL β-LG diallele knocks out milk powder solution, and (knocking out the total protein content in milk powder with β-LG diallele is
Tested material, dosage are 5mg total protein/gBW);
β-LG diallele knocks out milk powder group 2: respectively in experiment the 0th day, the 7th day, the 14th day, the 21st day and the 28th
It, every mouse oral stomach-filling 0.2mL β-LG diallele knocks out milk powder solution and (knocks out milk with β-LG diallele
Total protein content in powder is tested material, and dosage is 1mg total protein/gBW);It tests the 42nd day, every mouse oral stomach-filling
0.2mL β-LG diallele knocks out milk powder solution, and (knocking out the total protein content in milk powder with β-LG diallele is
Tested material, dosage are 10mg total protein/gBW);
β-LG diallele knocks out milk powder group 3: respectively in experiment the 0th day, the 7th day, the 14th day, the 21st day and the 28th
It, every mouse oral stomach-filling 0.2mL β-LG diallele knocks out milk powder solution and (knocks out milk with β-LG diallele
Total protein content in powder is tested material, and dosage is 2mg total protein/gBW);It tests the 42nd day, every mouse oral stomach-filling
0.2mL β-LG diallele knocks out milk powder solution, and (knocking out the total protein content in milk powder with β-LG diallele is
Tested material, dosage are 20mg total protein/gBW).
During test, upgrowth situation (figure and features, feed amount and spiritual shape including mouse of mouse are observed weekly
State etc.).
When testing the 42nd -day-old of stimulation (i.e. dosage increases to 1- times and stimulated), appropriate vaseline is smeared using probe
Electronic thermometer measures Temperature changing of the mouse before and after stimulation.As a result see that (wild type milk is non-transgenic cow milk powder to Fig. 7
Group 1, non-transgenic cow milk powder group 2 and non-transgenic cow milk powder group 3 are as repeating to be averaged three times as a result, β-LG clpp gene
Except milk is that β-LG diallele knocks out milk powder group 1, β-LG diallele knocks out milk powder group 2 and the double equipotential bases of β-LG
Because knocking out milk powder group 3 as the result for repeating to be averaged three times).The result shows that β-LG diallele knocks out milk powder
The anal intestine temperature change of administering transgenic mouse is significantly lower than non-transgenic cow milk powder, further illustrates that β-LG diallele knocks out
The sensitization of milk powder reduces.
The above results show that β-LG diallele knocks out milk powder and milk sensitization is greatly lowered.
<110>China Agricultural University
<120>a kind of method and its application for the ox for cultivating production low irritability milk
<160> 5
<170> PatentIn version 3.5
<210> 1
<211> 4894
<212> DNA
<213>artificial sequence
<220>
<223>
<400> 1
tcctgcttgg cctcgaatgg aagaaggcct cctattgtcc tcgtagagga agcaacccca 60
gggcccaagg ataggccagg ggggattcgg ggaaccgcgt ggctgggggc ccggcccggg 120
ctggctggct ggccctcctc ctgtataagg ccccgagccc actgtctcag ccctccactc 180
cctgcagagc tcagaagcgt gaccccagct gcagccatga agtgcctcct gcttgccctg 240
gccctcactt gtggcgccca ggccctcatt gtcacccaga ccatgaaggg cctggatatc 300
cagaaggttc gagggtgccc gggtgggtgg tgagttgcag ggcaggcagg ggagctgggc 360
ctcagagacc aagggaggct gtgacgtctg ggattcccat cagtcagcta gagccgcctg 420
acaaatcgcc cgccagggca gcttcaacca ggcgtttagt gtcttgcatt ctggaggctg 480
gaagcctgca atccgggcat cggcccagct ggcttctcct gcggccactc tccggggagc 540
agacagccat cttctccctg tgtcctttgc gtgccctggt ttcctcttcc tgtgaggtca 600
ccaggcctgc tggatccacg cccgcccaca cagcctcacg taacctttgt catctcttta 660
aaggccgtgt ctccagtcct gtgttgaggt tctgggggtt aatgggacac agttcagccc 720
ctaaaagagt cactctgccc ctcaaatttt ccccacctcc agctatgtct ccccaagatc 780
caaatgttgc cacgtgtgcg ggggctcatc tgggtccctc tttgggctca gagtgagtct 840
ggggagagca ttcctcaggg tgccgagttg gggggagcat ctcagggctg cccaggccag 900
ggtgggacag agagcccact gtggggctgg gggccccttc ccgcccctgg agtgcagctc 960
aaggtccctc cccaggtggc ggggacttgg tactccttgg ccatggcggc cagcgacatc 1020
tccctgctgg acgcccagag tgcccccctg agagtgtatg tggaggagct gaagcccacc 1080
cctgagggcg acctggagat cctgctgcag aaatggtggg cgtccccccc aaaaaaagca 1140
tggaaccccc actccccagg gatatggacc cccccggggt ggggtgcagg agggaccagg 1200
gccccagggc tggggaacgg ggcttggagt ttcctggtac ccctggaggt ccacccaagg 1260
ctgcttatcc agggctttct ctttcttttt ttcccccaac ttttattaat ttgatgcttc 1320
agaacatcat caaacaaatg aacacaaaac atcattttcg ttaacttgga aggggagata 1380
aaatccactg aagtggaaat gcataggaaa gatacataca gtaaggcagg tattctgaat 1440
tcgctgttag tttgaggatt acaaatgcac ttgagcaaca gagagacgtt ttcattattt 1500
ctggtctgaa cagctcagta tctaaaatga acaagatgtc atggagacaa agccggcggg 1560
ggagaggccc gtgtgaaggc cgctgggcgg ctgcagacct gggtcctcgg ggcccaggca 1620
gttcccacta ccagccctgt ccaccctcag acgggggtca gagtgcagga gagagctggg 1680
tgggtgtggg ggcagagatg gggacctgaa ccccaggact gccttttggg gtgcctgtgg 1740
tcaaggctct ccccaacctt ttctccctgg ctccatctga cttctcctgg cccatccacc 1800
cggtcacctg tggccccaga ggtgacagtg agtgcagcca aggccggttg gccagccggc 1860
cccctatgcc cacgccaccc gcctccagcc cctcctgggg ccgccttctg cccctggccc 1920
tcagttcatc ctgatgaaaa tggtccatgc ccgtggctca gaaagcagct gtctttcagg 1980
gagaacggtg agtgtgctca gaagaagatc attgcagaaa aaaccaagat ccctgcggtg 2040
ttcaagatcg atggtgagtg ctgggtcccc aggggacgcc caccaccccc cagggactgt 2100
gggcaggtgc agggggctgg cgtcaggccc cgagatgcta aggggctggt ggtgatgaag 2160
acactgccgt gccacctgct tccctggcct ccctgccacc tgcccggggc cttggggccg 2220
gtggccgtgg gcaggtcccg gctgggcagg tctgacaccc cagggtgaca cccgagctct 2280
ctttgctgag ggtggggtgg tgctcggggc cctcaggctg agctcaggag gtccctgtgc 2340
ccacccaggg gtaaccgaga gccgctgccc gctccagggg tccaggtgcc ccacgatccc 2400
agcccacccc acggctcctt catctcctga agacgaactc tgtccgccct cgctcattca 2460
cttgtttgtc ctaaatccaa gatgagaaag cttcgaggtg gggttggggt tccatcaggg 2520
cctgcccttc cgccgggcag cctgggccac atctgccctt ggcctcttca ggactcactc 2580
tgactggagg ccctgcactg actgatgcca gggtgcccag cccagggtct cctgtgccat 2640
ccggctgcac ggggtttgga tgctggtcct gcccccaagc tgcccagaca ctgcagggca 2700
gctggggcca cccgcaggcc tcggtcaggg agagccccag ctgcccccgc tcagcgctgc 2760
cccccaacaa ttccccagtc ctcaggacgc atccctcttc ccttgctggg cagtgttcag 2820
ccccacccga gatcggggga agccctattt cttgaccact ccggtccctg ggggagggcg 2880
gcctcagact gagtggtgag tgttcccaag tccaggaggt ggtggagggt ccctggcgga 2940
tccagagttg ggcttccaga gtgagggctt cctgggcccc atgtgcctgg cagtggcagc 3000
agggaagggg ccacaccatt ttggggctgg gggatgccag agggcgctcc ccaccccgtc 3060
ctcaccaagt ggtgaccccg ggggagcccc gctggttgtg gggggcgctg ggggctgacc 3120
agaaaccccc ctcctgctgg aactcacttt cctcctgtct tgatctctac cagccttgaa 3180
cgagaacaaa gtccttgtgc tggacaccga ctacaaaaag tacctgctct tctgcatgga 3240
gaacagtgct gagcccgagc aaagcctggt ctgccagtgc ctgggtgggt gccaaccctg 3300
gctgcccagg gagaccagct gtgtggtcct cgctgcaacg gggccggggg ggacggtggg 3360
agcagggagc ttgattccca ggaggaggag ggatgggggg tccccgagtc ccgccaggag 3420
agggtggtca tataccggga gccggtgtcc tgggggtctg tgggtgactg gggacggggg 3480
ccagacacac aggctgggag acggggggct gcagcgctct ggtgtgacca tcacgatgga 3540
gccggcggtc actatgaatc taacagcctt tgttaccggg gagtttcaat tatttcatca 3600
aataagaact caggcacaaa gctgtctttc aactgtcacg tcctgaaaac aaatggcagg 3660
tgacattttc catgccatag cagtgccact gggcattttc agggcccatg tgccaggagg 3720
gcgtgggcat cggcgagtgg aggctcctgg ccgtgtcagc tggcccaggg ggaggagggg 3780
acccagacag ccagaggtgg ggagcaggct ttccccctgt gacgctgcag acccaccgca 3840
ctgccctggg aggaagggga gggaactggg ccaaggggga agggcaggtg tgctggaggc 3900
caaggcagac ctgcacacca ccctggagag caggggttga ccccgtcccg gccccacagt 3960
caggaccccg gaggtggacg acgaggccct ggagaaattc gacaaagccc tcaaggccct 4020
gcccatgcac atccggctgt ccttcaaccc aacccagctg gagggtgagc acccaggccc 4080
caccctgctc ctggggcagg aagccacccg gcccaggacc acctcctccc atggtgaccc 4140
ccagctcccc aggcctcccg ggaggatgga gacggggtgc agggccccga ggtggccccc 4200
tccccacccc ctccccagct ccctctgtcc tggggtgtcc agtcccatcc tgacgctccc 4260
ccgccacggc tctccctccc ccacagagca gtgccacatc taggtgagcc cctgccggcg 4320
cctctggggt aagctgcctg ccctgcccca cgtcctgggc acacacatgg ggtaggggtt 4380
cttggttggg cccgggagcc cccattaggc cctggggtcc ccccgtagga atggctggaa 4440
gctggggtcc ttcctggaga ctacagagcc ggctggccac atgctcgctc ttgtggggtg 4500
acctgtgtcc tggcctcact cacacgctga tctcctccac ctccttcctg gcagacctaa 4560
gggccaaggt ggaggctcag gaagtggaca cctaaggggg aggctagggg ggtccttctc 4620
ccaaggaggg gccgtcctga atccccagcc acggacaggc tggcaagggt ctggcaggta 4680
ccccaggaat cacaggggag ccccatgtcc atttcagagc ccgggagcct tggcccctct 4740
ggggacagac gatgtcatcc ccgcctgccc catcagggga ccaggaggaa ccgggaccac 4800
attcacccct cctgggaccc aggcccctcc aggcccctcc tggggcctcc tgcttggggc 4860
cgctcctcct tcagcaataa aggcataaac ctgt 4894
<210> 2
<211> 4878
<212> DNA
<213>artificial sequence
<220>
<223>
<400> 2
tcctgcttgg cctcgaatgg aagaaggcct cctattgtcc tcgtagagga agcaacccca 60
gggcccaagg ataggccagg ggggattcgg ggaaccgcgt ggctgggggc ccggcccggg 120
ctggctggct ggccctcctc ctgtataagg ccccgagccc actgtctcag ccctccactc 180
cctgcagagc tcagaagcgt gaccccagct gcagccatga agtgcctcct gcttgccctg 240
gccctcactt gtggcgccca ggccccatga agggcctgga tatccagaag gttcgagggt 300
gcccgggtgg gtggtgagtt gcagggcagg caggggagct gggcctcaga gaccaaggga 360
ggctgtgacg tctgggattc ccatcagtca gctagagccg cctgacaaat cgcccgccag 420
ggcagcttca accaggcgtt tagtgtcttg cattctggag gctggaagcc tgcaatccgg 480
gcatcggccc agctggcttc tcctgcggcc actctccggg gagcagacag ccatcttctc 540
cctgtgtcct ttgcgtgccc tggtttcctc ttcctgtgag gtcaccaggc ctgctggatc 600
cacgcccgcc cacacagcct cacgtaacct ttgtcatctc tttaaaggcc gtgtctccag 660
tcctgtgttg aggttctggg ggttaatggg acacagttca gcccctaaaa gagtcactct 720
gcccctcaaa ttttccccac ctccagctat gtctccccaa gatccaaatg ttgccacgtg 780
tgcgggggct catctgggtc cctctttggg ctcagagtga gtctggggag agcattcctc 840
agggtgccga gttgggggga gcatctcagg gctgcccagg ccagggtggg acagagagcc 900
cactgtgggg ctgggggccc cttcccgccc ctggagtgca gctcaaggtc cctccccagg 960
tggcggggac ttggtactcc ttggccatgg cggccagcga catctccctg ctggacgccc 1020
agagtgcccc cctgagagtg tatgtggagg agctgaagcc cacccctgag ggcgacctgg 1080
agatcctgct gcagaaatgg tgggcgtccc ccccaaaaaa agcatggaac ccccactccc 1140
cagggatatg gacccccccg gggtggggtg caggagggac cagggcccca gggctgggga 1200
acggggcttg gagtttcctg gtacccctgg aggtccaccc aaggctgctt atccagggct 1260
ttctctttct ttttttcccc caacttttat taatttgatg cttcagaaca tcatcaaaca 1320
aatgaacaca aaacatcatt ttcgttaact tggaagggga gataaaatcc actgaagtgg 1380
aaatgcatag gaaagataca tacagtaagg caggtattct gaattcgctg ttagtttgag 1440
gattacaaat gcacttgagc aacagagaga cgttttcatt atttctggtc tgaacagctc 1500
agtatctaaa atgaacaaga tgtcatggag acaaagccgg cgggggagag gcccgtgtga 1560
aggccgctgg gcggctgcag acctgggtcc tcggggccca ggcagttccc actaccagcc 1620
ctgtccaccc tcagacgggg gtcagagtgc aggagagagc tgggtgggtg tgggggcaga 1680
gatggggacc tgaaccccag gactgccttt tggggtgcct gtggtcaagg ctctccccaa 1740
ccttttctcc ctggctccat ctgacttctc ctggcccatc cacccggtca cctgtggccc 1800
cagaggtgac agtgagtgca gccaaggccg gttggccagc cggcccccta tgcccacgcc 1860
acccgcctcc agcccctcct ggggccgcct tctgcccctg gccctcagtt catcctgatg 1920
aaaatggtcc atgcccgtgg ctcagaaagc agctgtcttt cagggagaac ggtgagtgtg 1980
ctcagaagaa gatcattgca gaaaaaacca agatccctgc ggtgttcaag atcgatggtg 2040
agtgctgggt ccccagggga cgcccaccac cccccaggga ctgtgggcag gtgcaggggg 2100
ctggcgtcag gccccgagat gctaaggggc tggtggtgat gaagacactg ccgtgccacc 2160
tgcttccctg gcctccctgc cacctgcccg gggccttggg gccggtggcc gtgggcaggt 2220
cccggctggg caggtctgac accccagggt gacacccgag ctctctttgc tgagggtggg 2280
gtggtgctcg gggccctcag gctgagctca ggaggtccct gtgcccaccc aggggtaacc 2340
gagagccgct gcccgctcca ggggtccagg tgccccacga tcccagccca ccccacggct 2400
ccttcatctc ctgaagacga actctgtccg ccctcgctca ttcacttgtt tgtcctaaat 2460
ccaagatgag aaagcttcga ggtggggttg gggttccatc agggcctgcc cttccgccgg 2520
gcagcctggg ccacatctgc ccttggcctc ttcaggactc actctgactg gaggccctgc 2580
actgactgat gccagggtgc ccagcccagg gtctcctgtg ccatccggct gcacggggtt 2640
tggatgctgg tcctgccccc aagctgccca gacactgcag ggcagctggg gccacccgca 2700
ggcctcggtc agggagagcc ccagctgccc ccgctcagcg ctgcccccca acaattcccc 2760
agtcctcagg acgcatccct cttcccttgc tgggcagtgt tcagccccac ccgagatcgg 2820
gggaagccct atttcttgac cactccggtc cctgggggag ggcggcctca gactgagtgg 2880
tgagtgttcc caagtccagg aggtggtgga gggtccctgg cggatccaga gttgggcttc 2940
cagagtgagg gcttcctggg ccccatgtgc ctggcagtgg cagcagggaa ggggccacac 3000
cattttgggg ctgggggatg ccagagggcg ctccccaccc cgtcctcacc aagtggtgac 3060
cccgggggag ccccgctggt tgtggggggc gctgggggct gaccagaaac ccccctcctg 3120
ctggaactca ctttcctcct gtcttgatct ctaccagcct tgaacgagaa caaagtcctt 3180
gtgctggaca ccgactacaa aaagtacctg ctcttctgca tggagaacag tgctgagccc 3240
gagcaaagcc tggtctgcca gtgcctgggt gggtgccaac cctggctgcc cagggagacc 3300
agctgtgtgg tcctcgctgc aacggggccg ggggggacgg tgggagcagg gagcttgatt 3360
cccaggagga ggagggatgg ggggtccccg agtcccgcca ggagagggtg gtcatatacc 3420
gggagccggt gtcctggggg tctgtgggtg actggggacg ggggccagac acacaggctg 3480
ggagacgggg ggctgcagcg ctctggtgtg accatcacga tggagccggc ggtcactatg 3540
aatctaacag cctttgttac cggggagttt caattatttc atcaaataag aactcaggca 3600
caaagctgtc tttcaactgt cacgtcctga aaacaaatgg caggtgacat tttccatgcc 3660
atagcagtgc cactgggcat tttcagggcc catgtgccag gagggcgtgg gcatcggcga 3720
gtggaggctc ctggccgtgt cagctggccc agggggagga ggggacccag acagccagag 3780
gtggggagca ggctttcccc ctgtgacgct gcagacccac cgcactgccc tgggaggaag 3840
gggagggaac tgggccaagg gggaagggca ggtgtgctgg aggccaaggc agacctgcac 3900
accaccctgg agagcagggg ttgaccccgt cccggcccca cagtcaggac cccggaggtg 3960
gacgacgagg ccctggagaa attcgacaaa gccctcaagg ccctgcccat gcacatccgg 4020
ctgtccttca acccaaccca gctggagggt gagcacccag gccccaccct gctcctgggg 4080
caggaagcca cccggcccag gaccacctcc tcccatggtg acccccagct ccccaggcct 4140
cccgggagga tggagacggg gtgcagggcc ccgaggtggc cccctcccca ccccctcccc 4200
agctccctct gtcctggggt gtccagtccc atcctgacgc tcccccgcca cggctctccc 4260
tcccccacag agcagtgcca catctaggtg agcccctgcc ggcgcctctg gggtaagctg 4320
cctgccctgc cccacgtcct gggcacacac atggggtagg ggttcttggt tgggcccggg 4380
agcccccatt aggccctggg gtccccccgt aggaatggct ggaagctggg gtccttcctg 4440
gagactacag agccggctgg ccacatgctc gctcttgtgg ggtgacctgt gtcctggcct 4500
cactcacacg ctgatctcct ccacctcctt cctggcagac ctaagggcca aggtggaggc 4560
tcaggaagtg gacacctaag ggggaggcta ggggggtcct tctcccaagg aggggccgtc 4620
ctgaatcccc agccacggac aggctggcaa gggtctggca ggtaccccag gaatcacagg 4680
ggagccccat gtccatttca gagcccggga gccttggccc ctctggggac agacgatgtc 4740
atccccgcct gccccatcag gggaccagga ggaaccggga ccacattcac ccctcctggg 4800
acccaggccc ctccaggccc ctcctggggc ctcctgcttg gggccgctcc tccttcagca 4860
ataaaggcat aaacctgt 4878
<210> 3
<211> 4877
<212> DNA
<213>artificial sequence
<220>
<223>
<400> 3
tcctgcttgg cctcgaatgg aagaaggcct cctattgtcc tcgtagagga agcaacccca 60
gggcccaagg ataggccagg ggggattcgg ggaaccgcgt ggctgggggc ccggcccggg 120
ctggctggct ggccctcctc ctgtataagg ccccgagccc actgtctcag ccctccactc 180
cctgcagagc tcagaagcgt gaccccagct gcagccatga agtgcctcct gcttgccctg 240
gccctcactt gtggcgccca ggcccatgaa gggcctggat atccagaagg ttcgagggtg 300
cccgggtggg tggtgagttg cagggcaggc aggggagctg ggcctcagag accaagggag 360
gctgtgacgt ctgggattcc catcagtcag ctagagccgc ctgacaaatc gcccgccagg 420
gcagcttcaa ccaggcgttt agtgtcttgc attctggagg ctggaagcct gcaatccggg 480
catcggccca gctggcttct cctgcggcca ctctccgggg agcagacagc catcttctcc 540
ctgtgtcctt tgcgtgccct ggtttcctct tcctgtgagg tcaccaggcc tgctggatcc 600
acgcccgccc acacagcctc acgtaacctt tgtcatctct ttaaaggccg tgtctccagt 660
cctgtgttga ggttctgggg gttaatggga cacagttcag cccctaaaag agtcactctg 720
cccctcaaat tttccccacc tccagctatg tctccccaag atccaaatgt tgccacgtgt 780
gcgggggctc atctgggtcc ctctttgggc tcagagtgag tctggggaga gcattcctca 840
gggtgccgag ttggggggag catctcaggg ctgcccaggc cagggtggga cagagagccc 900
actgtggggc tgggggcccc ttcccgcccc tggagtgcag ctcaaggtcc ctccccaggt 960
ggcggggact tggtactcct tggccatggc ggccagcgac atctccctgc tggacgccca 1020
gagtgccccc ctgagagtgt atgtggagga gctgaagccc acccctgagg gcgacctgga 1080
gatcctgctg cagaaatggt gggcgtcccc cccaaaaaaa gcatggaacc cccactcccc 1140
agggatatgg acccccccgg ggtggggtgc aggagggacc agggccccag ggctggggaa 1200
cggggcttgg agtttcctgg tacccctgga ggtccaccca aggctgctta tccagggctt 1260
tctctttctt tttttccccc aacttttatt aatttgatgc ttcagaacat catcaaacaa 1320
atgaacacaa aacatcattt tcgttaactt ggaaggggag ataaaatcca ctgaagtgga 1380
aatgcatagg aaagatacat acagtaaggc aggtattctg aattcgctgt tagtttgagg 1440
attacaaatg cacttgagca acagagagac gttttcatta tttctggtct gaacagctca 1500
gtatctaaaa tgaacaagat gtcatggaga caaagccggc gggggagagg cccgtgtgaa 1560
ggccgctggg cggctgcaga cctgggtcct cggggcccag gcagttccca ctaccagccc 1620
tgtccaccct cagacggggg tcagagtgca ggagagagct gggtgggtgt gggggcagag 1680
atggggacct gaaccccagg actgcctttt ggggtgcctg tggtcaaggc tctccccaac 1740
cttttctccc tggctccatc tgacttctcc tggcccatcc acccggtcac ctgtggcccc 1800
agaggtgaca gtgagtgcag ccaaggccgg ttggccagcc ggccccctat gcccacgcca 1860
cccgcctcca gcccctcctg gggccgcctt ctgcccctgg ccctcagttc atcctgatga 1920
aaatggtcca tgcccgtggc tcagaaagca gctgtctttc agggagaacg gtgagtgtgc 1980
tcagaagaag atcattgcag aaaaaaccaa gatccctgcg gtgttcaaga tcgatggtga 2040
gtgctgggtc cccaggggac gcccaccacc ccccagggac tgtgggcagg tgcagggggc 2100
tggcgtcagg ccccgagatg ctaaggggct ggtggtgatg aagacactgc cgtgccacct 2160
gcttccctgg cctccctgcc acctgcccgg ggccttgggg ccggtggccg tgggcaggtc 2220
ccggctgggc aggtctgaca ccccagggtg acacccgagc tctctttgct gagggtgggg 2280
tggtgctcgg ggccctcagg ctgagctcag gaggtccctg tgcccaccca ggggtaaccg 2340
agagccgctg cccgctccag gggtccaggt gccccacgat cccagcccac cccacggctc 2400
cttcatctcc tgaagacgaa ctctgtccgc cctcgctcat tcacttgttt gtcctaaatc 2460
caagatgaga aagcttcgag gtggggttgg ggttccatca gggcctgccc ttccgccggg 2520
cagcctgggc cacatctgcc cttggcctct tcaggactca ctctgactgg aggccctgca 2580
ctgactgatg ccagggtgcc cagcccaggg tctcctgtgc catccggctg cacggggttt 2640
ggatgctggt cctgccccca agctgcccag acactgcagg gcagctgggg ccacccgcag 2700
gcctcggtca gggagagccc cagctgcccc cgctcagcgc tgccccccaa caattcccca 2760
gtcctcagga cgcatccctc ttcccttgct gggcagtgtt cagccccacc cgagatcggg 2820
ggaagcccta tttcttgacc actccggtcc ctgggggagg gcggcctcag actgagtggt 2880
gagtgttccc aagtccagga ggtggtggag ggtccctggc ggatccagag ttgggcttcc 2940
agagtgaggg cttcctgggc cccatgtgcc tggcagtggc agcagggaag gggccacacc 3000
attttggggc tgggggatgc cagagggcgc tccccacccc gtcctcacca agtggtgacc 3060
ccgggggagc cccgctggtt gtggggggcg ctgggggctg accagaaacc cccctcctgc 3120
tggaactcac tttcctcctg tcttgatctc taccagcctt gaacgagaac aaagtccttg 3180
tgctggacac cgactacaaa aagtacctgc tcttctgcat ggagaacagt gctgagcccg 3240
agcaaagcct ggtctgccag tgcctgggtg ggtgccaacc ctggctgccc agggagacca 3300
gctgtgtggt cctcgctgca acggggccgg gggggacggt gggagcaggg agcttgattc 3360
ccaggaggag gagggatggg gggtccccga gtcccgccag gagagggtgg tcatataccg 3420
ggagccggtg tcctgggggt ctgtgggtga ctggggacgg gggccagaca cacaggctgg 3480
gagacggggg gctgcagcgc tctggtgtga ccatcacgat ggagccggcg gtcactatga 3540
atctaacagc ctttgttacc ggggagtttc aattatttca tcaaataaga actcaggcac 3600
aaagctgtct ttcaactgtc acgtcctgaa aacaaatggc aggtgacatt ttccatgcca 3660
tagcagtgcc actgggcatt ttcagggccc atgtgccagg agggcgtggg catcggcgag 3720
tggaggctcc tggccgtgtc agctggccca gggggaggag gggacccaga cagccagagg 3780
tggggagcag gctttccccc tgtgacgctg cagacccacc gcactgccct gggaggaagg 3840
ggagggaact gggccaaggg ggaagggcag gtgtgctgga ggccaaggca gacctgcaca 3900
ccaccctgga gagcaggggt tgaccccgtc ccggccccac agtcaggacc ccggaggtgg 3960
acgacgaggc cctggagaaa ttcgacaaag ccctcaaggc cctgcccatg cacatccggc 4020
tgtccttcaa cccaacccag ctggagggtg agcacccagg ccccaccctg ctcctggggc 4080
aggaagccac ccggcccagg accacctcct cccatggtga cccccagctc cccaggcctc 4140
ccgggaggat ggagacgggg tgcagggccc cgaggtggcc ccctccccac cccctcccca 4200
gctccctctg tcctggggtg tccagtccca tcctgacgct cccccgccac ggctctccct 4260
cccccacaga gcagtgccac atctaggtga gcccctgccg gcgcctctgg ggtaagctgc 4320
ctgccctgcc ccacgtcctg ggcacacaca tggggtaggg gttcttggtt gggcccggga 4380
gcccccatta ggccctgggg tccccccgta ggaatggctg gaagctgggg tccttcctgg 4440
agactacaga gccggctggc cacatgctcg ctcttgtggg gtgacctgtg tcctggcctc 4500
actcacacgc tgatctcctc cacctccttc ctggcagacc taagggccaa ggtggaggct 4560
caggaagtgg acacctaagg gggaggctag gggggtcctt ctcccaagga ggggccgtcc 4620
tgaatcccca gccacggaca ggctggcaag ggtctggcag gtaccccagg aatcacaggg 4680
gagccccatg tccatttcag agcccgggag ccttggcccc tctggggaca gacgatgtca 4740
tccccgcctg ccccatcagg ggaccaggag gaaccgggac cacattcacc cctcctggga 4800
cccaggcccc tccaggcccc tcctggggcc tcctgcttgg ggccgctcct ccttcagcaa 4860
taaaggcata aacctgt 4877
<210> 4
<211> 4877
<212> DNA
<213>artificial sequence
<220>
<223>
<400> 4
cccaggccct cattgtcacc cagaccatga agggcctgga 40
<210> 5
<211> 252
<212> PRT
<213>artificial sequence
<220>
<223>
<400> 5
Met Lys Cys Leu Leu Leu Ala Leu Ala Leu Thr Cys Gly Ala Gln Ala
1 5 10 15
Leu Ile Val Thr Gln Thr Met Lys Gly Leu Asp Ile Gln Lys Val Ala
20 25 30
Gly Thr Trp Tyr Ser Leu Ala Met Ala Ala Ser Asp Ile Ser Leu Leu
35 40 45
Asp Ala Gln Ser Ala Pro Leu Arg Val Tyr Val Glu Glu Leu Lys Pro
50 55 60
Thr Pro Glu Gly Asp Leu Glu Ile Leu Leu Gln Lys Trp Glu Asn Gly
65 70 75 80
Glu Cys Ala Gln Lys Lys Ile Ile Ala Glu Lys Thr Lys Ile Pro Ala
85 90 95
Val Phe Lys Ile Asp Ala Leu Asn Glu Asn Lys Val Leu Val Leu Asp
100 105 110
Thr Asp Tyr Lys Lys Tyr Leu Leu Phe Cys Met Glu Asn Ser Ala Glu
115 120 125
Pro Glu Gln Ser Leu Ala Cys Gln Cys Leu Val Arg Thr Pro Glu Val
130 135 140
Asp Asp Glu Ala Leu Glu Lys Phe Asp Lys Ala Leu Lys Ala Leu Pro
145 150 155 160
Met His Ile Arg Leu Ser Phe Asn Pro Thr Gln Leu Glu Gly Glu His
165 170 175
Pro Gly Pro Thr Leu Leu Leu Gly Gln Glu Ala Thr Arg Pro Arg Thr
180 185 190
Thr Ser Ser His Gly Asp Pro Gln Leu Pro Arg Pro Pro Gly Arg Met
195 200 205
Glu Thr Gly Cys Arg Ala Pro Arg Trp Pro Pro Pro His Pro Leu Pro
210 215 220
Ser Ser Leu Cys Pro Gly Val Ser Ser Pro Ile Leu Thr Leu Pro Arg
225 230 235 240
His Gly Ser Pro Ser Pro Thr Glu Gln Cys His Ile
245 250
Claims (10)
1. the method for cultivating the ox of production low irritability milk includes the following steps: to inhibit the β-LG albumen in cow genome group that sets out
Synthesis and/or expression quantity and/or activity, obtain transgenic cow;Compared with the ox that sets out, the milk sensitization of transgenic cow production
It reduces.
2. the method as described in claim 1, it is characterised in that: described " inhibition is set out the synthesis of β-LG albumen in cow genome group
And/or expression quantity and/or activity " carried out by way of gene site-directed editor, RNA interference, homologous recombination or gene knockout;Institute
Gene site-directed editor is stated to carry out using cow genome group editor's carrier.
3. method according to claim 1 or 2, it is characterised in that: described " inhibition is set out the conjunction of β-LG albumen in cow genome group
At and/or expression quantity and/or activity " be to send out the nucleic acid molecule of the β-LG gene on two homologues for the ox that sets out
Raw frameshift mutation.
4. the method for cultivating the ox of production low irritability milk, including step (1): importing cow genome group to bovine fibroblasts and compile
Carrier is collected, the donorcells that genotype is diallele saltant type are obtained;
The diallele saltant type is that the nucleic acid molecule of the β-LG gene on two homologues of ox changes,
It is this to change the synthesis for inhibiting β-LG albumen and/or expression quantity and/or activity.
5. method as claimed in claim 4, it is characterised in that: it is described " β-LG gene on two homologues of ox
Nucleic acid molecule changes " be ox two homologues on β-LG gene nucleic acid molecule occurs frameshit dash forward
Become.
6. method as described in claim 4 or 5, it is characterised in that: the method also includes step (2): completing step (1)
Afterwards, the nucleus of the donorcells is moved into the bovine oocyte for removing nucleus, development forms reconstruct embryo, then moves into
Cow uteri, childbirth obtain the ox of production low irritability milk.
7. the method as described in claim 2,4,5 or 6, it is characterised in that: cow genome group editor's carrier is zinc finger nucleic acid
Zymophore pZFN;The target DNA that the Zinc finger nuclease carrier pZFN is identified in cow genome group is the DNA for encoding β-LG albumen
Segment.
8. a kind of method of detection or auxiliary detection milk sensitization, includes the following steps: two homologous dyes for detecting ox to be measured
β-LG gene on colour solid is wild type or diallele saltant type, and genotype is the ox to be measured of diallele saltant type
The sensitization of the milk of production is lower than or the candidate ox to be measured lower than genotype for wild type;
The diallele saltant type is that the nucleic acid molecule of the β-LG gene on two homologues of ox moves
Code mutation;The wild type does not occur frameshit for the nucleic acid molecule of the β-LG gene on two homologues of ox and dashes forward
Become.
9. the Zinc finger nuclease carrier pZFN of cow genome group editor a kind of, it is characterised in that: the Zinc finger nuclease carrier pZFN
The target DNA identified in cow genome group is the DNA fragmentation for encoding β-LG albumen.
10. the nucleic acid molecule of the β-LG gene on two homologues of ox to that the method or production of frameshift mutation occur
Product will inhibit the synthesis of β-LG albumen and/or expression quantity and/or active method or product in cow genome group, give birth to cultivating
It produces the ox of low irritability milk and/or reduces milk sensitization and/or produce the application in low irritability milk.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811219908.6A CN109321600A (en) | 2018-10-19 | 2018-10-19 | A kind of method and its application of ox that cultivating production low irritability milk |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811219908.6A CN109321600A (en) | 2018-10-19 | 2018-10-19 | A kind of method and its application of ox that cultivating production low irritability milk |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109321600A true CN109321600A (en) | 2019-02-12 |
Family
ID=65262035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811219908.6A Pending CN109321600A (en) | 2018-10-19 | 2018-10-19 | A kind of method and its application of ox that cultivating production low irritability milk |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109321600A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111334529A (en) * | 2020-05-20 | 2020-06-26 | 中国农业大学 | Method for preparing accurate BLG gene knockout cattle by using third generation base editor |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1865448A (en) * | 2005-05-19 | 2006-11-22 | 李宁 | Transgenic cow obtaining method |
CN102212545A (en) * | 2011-04-07 | 2011-10-12 | 北京济福霖生物技术有限公司 | Method for knocking out cattle beta-lactoglobulin gene by using zinc finger nucleases (ZFNs) |
CN103088046A (en) * | 2013-01-18 | 2013-05-08 | 内蒙古大学 | Method for knocking out ZFNs (zinc finger nucleases)-mediated bovine MSTN (myostatin) gene and integrating exogenous gene at fixed point |
CN103160534A (en) * | 2013-03-26 | 2013-06-19 | 西北农林科技大学 | Universal type bovine beta-casein site gene targeting vector and preparation method thereof |
CN103923940A (en) * | 2014-04-16 | 2014-07-16 | 中国农业大学 | Site-specific integration method of exogenous genes |
WO2015168125A1 (en) * | 2014-04-28 | 2015-11-05 | Recombinetics, Inc. | Multiplex gene editing in swine |
CN105063023A (en) * | 2015-07-24 | 2015-11-18 | 中国农业科学院北京畜牧兽医研究所 | Zinc finger nuclease-mediated porcine MSTN (myostatin) gene mutation sequence and application thereof |
-
2018
- 2018-10-19 CN CN201811219908.6A patent/CN109321600A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1865448A (en) * | 2005-05-19 | 2006-11-22 | 李宁 | Transgenic cow obtaining method |
CN102212545A (en) * | 2011-04-07 | 2011-10-12 | 北京济福霖生物技术有限公司 | Method for knocking out cattle beta-lactoglobulin gene by using zinc finger nucleases (ZFNs) |
CN103088046A (en) * | 2013-01-18 | 2013-05-08 | 内蒙古大学 | Method for knocking out ZFNs (zinc finger nucleases)-mediated bovine MSTN (myostatin) gene and integrating exogenous gene at fixed point |
CN103160534A (en) * | 2013-03-26 | 2013-06-19 | 西北农林科技大学 | Universal type bovine beta-casein site gene targeting vector and preparation method thereof |
CN103923940A (en) * | 2014-04-16 | 2014-07-16 | 中国农业大学 | Site-specific integration method of exogenous genes |
WO2015168125A1 (en) * | 2014-04-28 | 2015-11-05 | Recombinetics, Inc. | Multiplex gene editing in swine |
CN105063023A (en) * | 2015-07-24 | 2015-11-18 | 中国农业科学院北京畜牧兽医研究所 | Zinc finger nuclease-mediated porcine MSTN (myostatin) gene mutation sequence and application thereof |
Non-Patent Citations (1)
Title |
---|
薛可等: "利用Red同源重组系统进行牛β酪蛋白基因敲除", 《遗传》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111334529A (en) * | 2020-05-20 | 2020-06-26 | 中国农业大学 | Method for preparing accurate BLG gene knockout cattle by using third generation base editor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Festing | Inbred strains of mice | |
CN109706184A (en) | The method for building up of self-closing disease model dog | |
CN115968834A (en) | Preparation method and application of RS1 point mutation mouse model | |
JP5542928B2 (en) | Method for producing transformed earthworm using worm's gonad regeneration ability, transformed earthworm produced thereby, and method for producing recombinant protein from body fluid of transformed earthworm | |
Epstein et al. | Production of viable adult trisomy 17 reversible diploid mouse chimeras. | |
CN107840880A (en) | A kind of biologically active polypeptide GLNYYQQKPVA and its preparation method and application | |
CN109321600A (en) | A kind of method and its application of ox that cultivating production low irritability milk | |
WO2021057806A1 (en) | Method for establishing diabetes disease model dog | |
Ma et al. | Expression of recombinant human α-lactalbumin in milk of transgenic cloned pigs is sufficient to enhance intestinal growth and weight gain of suckling piglets | |
CN111876418B (en) | Method for establishing congenital black Mongolian model dogs | |
CN100480390C (en) | Transgenic cow obtaining method | |
CN108559749A (en) | It is a kind of can be expressed in ox body number of base missing myostatin gene and its application | |
US11653636B2 (en) | Method of making a rat model of retinal degeneration and rat model made thereby | |
CN110846330B (en) | Mutant gene and application thereof in constructing small pig model with webbed foot disease | |
CN103923215B (en) | Make material and the application thereof of ACC-α gene promoter P III inactivation | |
Stephenson et al. | Inter-specific relationships of Leiopelma (Amphibia: Anura): further karyological evidence | |
CN111334529B (en) | Method for preparing accurate BLG gene knockout cattle by using third generation base editor | |
Glass | Human heredity and ethical problems | |
CN115820735B (en) | Myopia rat model caused by Timp4 gene defect and construction method and application thereof | |
KR101174493B1 (en) | Transgenic pig with overexpression of mouse PEA15, and method for preparing thereof | |
CN101899445A (en) | Specificity overexpression mouse model of transduction iASPPsv cancer gene in hemopoietic system and preparation method and use thereof | |
CN103145824B (en) | Mutant cryptochromel 1 and transgenic pig of mutant cryptochromel 1 | |
JP4219789B2 (en) | Bone marrow-derived immortalized dendritic cell line | |
EP4223308A1 (en) | Composition including plgf for prevention or treatment of neuropsychologic disease | |
CN1891821B (en) | Production method of animal cell with human lysozyme gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190212 |
|
RJ01 | Rejection of invention patent application after publication |